Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Protagonist Therapeutics stock

PTGX
US74366E1029
A2AP32

Price

42.70
Today +/-
-0.44
Today %
-1.09 %
P

Protagonist Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Protagonist Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Protagonist Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Protagonist Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Protagonist Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Protagonist Therapeutics Stock Price History

DateProtagonist Therapeutics Price
11/13/202442.70 undefined
11/12/202443.17 undefined
11/11/202446.50 undefined
11/8/202446.23 undefined
11/7/202447.61 undefined
11/6/202447.60 undefined
11/5/202445.90 undefined
11/4/202446.76 undefined
11/1/202446.76 undefined
10/31/202445.84 undefined
10/30/202447.62 undefined
10/29/202448.43 undefined
10/28/202448.20 undefined
10/25/202447.26 undefined
10/24/202446.95 undefined
10/23/202446.59 undefined
10/22/202446.44 undefined
10/21/202445.96 undefined
10/18/202446.97 undefined
10/17/202447.02 undefined
10/16/202446.99 undefined

Protagonist Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Protagonist Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Protagonist Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Protagonist Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Protagonist Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Protagonist Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Protagonist Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Protagonist Therapeutics’s growth potential.

Protagonist Therapeutics Revenue, EBIT and net profit per share

DateProtagonist Therapeutics RevenueProtagonist Therapeutics EBITProtagonist Therapeutics Net Income
2029e536.14 M undefined0 undefined201.26 M undefined
2028e365.57 M undefined169.54 M undefined59.18 M undefined
2027e191.41 M undefined9.41 M undefined-46.56 M undefined
2026e197.19 M undefined-38.66 M undefined-118.31 M undefined
2025e163.93 M undefined-10.09 M undefined-85.66 M undefined
2024e298.16 M undefined114.79 M undefined118.85 M undefined
202360 M undefined-93.65 M undefined-78.96 M undefined
202226.58 M undefined-131.37 M undefined-127.39 M undefined
202127.36 M undefined-125.85 M undefined-125.55 M undefined
202028.63 M undefined-64.51 M undefined-66.15 M undefined
2019230,000 undefined-80.52 M undefined-77.19 M undefined
201830.93 M undefined-42.27 M undefined-38.92 M undefined
201720.06 M undefined-37.9 M undefined-36.96 M undefined
20160 undefined-32.67 M undefined-37.74 M undefined
20150 undefined-14.79 M undefined-14.93 M undefined
20140 undefined-9.32 M undefined-11.22 M undefined

Protagonist Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0002030028272660298163197191365536
----50.00---3.57-3.70130.77396.67-45.3020.86-3.0591.1046.85
----------------
0000000000000000
-11-14-37-36-38-77-66-125-127-78118-85-118-4659201
-27.27164.29-2.705.56102.63-14.2989.391.60-38.58-251.28-172.0338.82-61.02-228.26240.68
14.6614.6614.6617.6922.3625.8934.446.3249.0456.76000000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Protagonist Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Protagonist Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2014201520162017201820192020202120222023
                   
9.311.977.6144128.9133305.8326.9237.4341.62
0000000000
0000000000
0000000000
0.11.63.43.82.14.868.55.73.63
9.413.581147.8131137.8311.8335.4243.1345.25
0.40.60.60.90.97.76.46.74.62.15
0010.211.5002000
0000000000
0000000000
0000000000
0000.51.11.90.50.20.20.23
0.40.610.812.929.68.96.94.82.37
9.814.191.8160.7133147.4320.7342.3247.9347.62
                   
20.63700000000
00.1152.4222.2253.2297.8563.4709.7752.7952.49
-12.6-27.4-64.6-101.6-140.5-217.7-283.8-409.4-536.8-615.71
-0.1-0.1-0.20-0.2-0.20-0.3-0.4-0.11
0000000000
7.99.687.6120.6112.579.9279.6300215.5336.68
0.41.31.41.35.72.83.11.63.60.77
0.91.759.411.113.519.939.527.120.4
00031.99.419.117.32.90.50.1
0000000000
0000000000
1.336.442.626.235.440.34431.221.27
12.10009.80000
0000000000
0000.50.829.84.63.71.10
12.100.50.839.64.63.71.10
2.35.16.443.1277544.947.732.321.27
10.214.794163.7139.5154.9324.5347.7247.8357.95
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Protagonist Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Protagonist Therapeutics's financial health and stability.

Assets

Protagonist Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Protagonist Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Protagonist Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Protagonist Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (k)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2014201520162017201820192020202120222023
-11-14-37-36-38-77-66-125-127-78
000000001,0000
0000001,000000
10035-1826-19-3-7-19
1099141718365056
0000000000
0000000000
-7-14-293-49-41-72-107-108-70
0000000-100
0-8-59152-53-90-1591-39
0-7-58162-52-90-1492-38
0000000000
000009-10000
91710665243625813019171
91710665244624712918170
----------
0000000000
0-51785-23-49846260
-8.04-14.79-30.353.2-50.44-42.5-72.95-108.97-108.94-70.85
0000000000

Protagonist Therapeutics stock margins

The Protagonist Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Protagonist Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Protagonist Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Protagonist Therapeutics's sales revenue. A higher gross margin percentage indicates that the Protagonist Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Protagonist Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Protagonist Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Protagonist Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Protagonist Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Protagonist Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Protagonist Therapeutics Margin History

Protagonist Therapeutics Gross marginProtagonist Therapeutics Profit marginProtagonist Therapeutics EBIT marginProtagonist Therapeutics Profit margin
2029e0 %0 %37.54 %
2028e0 %46.38 %16.19 %
2027e0 %4.92 %-24.32 %
2026e0 %-19.61 %-60 %
2025e0 %-6.15 %-52.26 %
2024e0 %38.5 %39.86 %
20230 %-156.09 %-131.59 %
20220 %-494.24 %-479.27 %
20210 %-459.98 %-458.88 %
20200 %-225.32 %-231.05 %
20190 %-35,008.69 %-33,560.87 %
20180 %-136.66 %-125.83 %
20170 %-188.93 %-184.25 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %

Protagonist Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Protagonist Therapeutics earnings per share therefore indicates how much revenue Protagonist Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Protagonist Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Protagonist Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Protagonist Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Protagonist Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Protagonist Therapeutics Revenue, EBIT and net profit per share

DateProtagonist Therapeutics Sales per ShareProtagonist Therapeutics EBIT per shareProtagonist Therapeutics Earnings per Share
2029e9.1 undefined0 undefined3.42 undefined
2028e6.21 undefined0 undefined1 undefined
2027e3.25 undefined0 undefined-0.79 undefined
2026e3.35 undefined0 undefined-2.01 undefined
2025e2.78 undefined0 undefined-1.45 undefined
2024e5.06 undefined0 undefined2.02 undefined
20231.06 undefined-1.65 undefined-1.39 undefined
20220.54 undefined-2.68 undefined-2.6 undefined
20210.59 undefined-2.72 undefined-2.71 undefined
20200.83 undefined-1.88 undefined-1.92 undefined
20190.01 undefined-3.11 undefined-2.98 undefined
20181.38 undefined-1.89 undefined-1.74 undefined
20171.13 undefined-2.14 undefined-2.09 undefined
20160 undefined-2.23 undefined-2.57 undefined
20150 undefined-1.01 undefined-1.02 undefined
20140 undefined-0.64 undefined-0.77 undefined

Protagonist Therapeutics business model

Protagonist Therapeutics Inc is a biopharmaceutical company focused on the development and commercialization of novel peptide therapies. The company was founded in 2002 and is headquartered in Newark, California. The history of Protagonist Therapy began with the discovery of a new type of molecules called peptides, which can be used as potential drugs for various diseases. This discovery was the result of years of research and collaboration between academics and leading pharmaceutical companies. Protagonist Therapeutics' business model is focused on developing and distributing new peptide therapies in the pharmaceutical industry. The company works closely with leading academics and biotechnology companies to advance its research and development projects. Protagonist Therapeutics is divided into several divisions focusing on different therapeutic areas. These include gastrointestinal diseases, immunology, and oncology. Each division works on developing new peptide therapies specifically tailored to their respective therapeutic areas. One example of a product from Protagonist Therapeutics is PTG-300, which was developed for the treatment of iron deficiency anemia. PTG-300 is a synthetic peptide that promotes increased iron uptake in the body to combat iron deficiency. Another product from Protagonist Therapeutics is PTG-200, which was developed for the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. PTG-200 is a peptide that blocks the action of certain enzymes that amplify inflammation in the intestine. Overall, Protagonist Therapeutics aims to establish itself as a leading provider of peptide therapies in the pharmaceutical industry. The company has a strong financial foundation, including a successful IPO in 2016, and is continuously working on developing new products to expand and grow the company. Protagonist Therapeutics is one of the most popular companies on Eulerpool.com.

Protagonist Therapeutics SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Protagonist Therapeutics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Protagonist Therapeutics Revenue by Segment

Segmente2018
Financial Service Other100,000 USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Protagonist Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Protagonist Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Protagonist Therapeutics shares outstanding

The number of shares was Protagonist Therapeutics in 2023 — This indicates how many shares 56.764 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Protagonist Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Protagonist Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Protagonist Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Protagonist Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Protagonist Therapeutics.

Protagonist Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.62 -0.54  (12.86 %)2024 Q3
6/30/2024-0.61 -0.5  (18.53 %)2024 Q2
3/31/20241.22 3.26  (167.72 %)2024 Q1
12/31/2023-0.03 0.44  (1,397.94 %)2023 Q4
9/30/2023-0.71 -0.58  (18.04 %)2023 Q3
6/30/2023-0.66 -0.68  (-2.98 %)2023 Q2
3/31/2023-0.74 -0.67  (9.61 %)2023 Q1
12/31/2022-0.65 -0.69  (-5.97 %)2022 Q4
9/30/2022-0.89 -0.64  (27.72 %)2022 Q3
6/30/2022-0.95 -0.84  (11.13 %)2022 Q2
1
2
3
4

Eulerpool ESG Scorecard© for the Protagonist Therapeutics stock

Eulerpool World ESG Rating (EESG©)

51/ 100

🌱 Environment

19

👫 Social

91

🏛️ Governance

42

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees55
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Protagonist Therapeutics shareholders

%
Name
Stocks
Change
Date
9.91642 % Farallon Capital Management, L.L.C.5,840,773101,8006/30/2024
8.97522 % RTW Investments L.P.5,286,404-29,1106/30/2024
7.17981 % BlackRock Institutional Trust Company, N.A.4,228,907104,5986/30/2024
5.63547 % BVF Partners L.P.3,319,290-436,7006/30/2024
5.48889 % The Vanguard Group, Inc.3,232,95950,5026/30/2024
5.40499 % State Street Global Advisors (US)3,183,5421,101,2189/30/2024
4.15821 % Johnson & Johnson Innovation-JJDC, Inc.2,449,18306/30/2024
3.46445 % Jefferies LLC2,040,561860,0006/30/2024
3.39786 % Adage Capital Management, L.P.2,001,342-217,5266/30/2024
2.72314 % Adar1 Capital Management LLC1,603,932818,2776/30/2024
1
2
3
4
5
...
10

Protagonist Therapeutics Executives and Management Board

Dr. Dinesh Patel(66)
Protagonist Therapeutics President, Chief Executive Officer, Director (since 2008)
Compensation 5.99 M
Mr. Suneel Gupta(65)
Protagonist Therapeutics Chief Development Officer
Compensation 2.68 M
Mr. Bryan Giraudo(48)
Protagonist Therapeutics Independent Director
Compensation 196,440
Dr. Harold Selick(69)
Protagonist Therapeutics Independent Chairman of the Board
Compensation 188,940
Mr. William Waddill(66)
Protagonist Therapeutics Independent Director
Compensation 178,940
1
2
3

Protagonist Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer0,780,18-0,78-0,76-0,340,34
Ligand Pharmaceuticals Stock
Ligand Pharmaceuticals
SupplierCustomer0,660,810,880,840,390,33
Zealand Pharma Stock
Zealand Pharma
SupplierCustomer-0,79-0,370,600,830,66-0,02
1

Most common questions regarding Protagonist Therapeutics

What values and corporate philosophy does Protagonist Therapeutics represent?

Protagonist Therapeutics Inc is a biopharmaceutical company that is driven by a strong set of values and corporate philosophy. They are committed to discovering and developing innovative peptide-based therapeutics that have the potential to transform patients' lives. With a focus on developing first-in-class oral peptide drugs, Protagonist Therapeutics Inc strives to provide novel treatment options for patients suffering from serious diseases. Their corporate philosophy revolves around collaboration, innovation, and scientific excellence, aiming to deliver value to patients, healthcare providers, and stakeholders. By combining cutting-edge research and an unwavering dedication to patient-centered solutions, Protagonist Therapeutics Inc embodies a commitment to advancing healthcare.

In which countries and regions is Protagonist Therapeutics primarily present?

Protagonist Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Protagonist Therapeutics achieved?

Protagonist Therapeutics Inc has achieved several significant milestones in its journey. The company successfully completed Phase 2 clinical trials for its potential drug PTG-100, which showed promising results in treating ulcerative colitis. Additionally, Protagonist Therapeutics Inc entered a partnership with Janssen Biotech to develop and commercialize PTG-200 for the treatment of Crohn's disease. Moreover, the company received Fast Track designation from the U.S. FDA for PTG-200, highlighting its potential in addressing unmet medical needs. Protagonist Therapeutics Inc's dedication to advancing novel therapeutic options marks a commendable achievement in the field of biotechnology.

What is the history and background of the company Protagonist Therapeutics?

Protagonist Therapeutics Inc. is a biopharmaceutical company specializing in the development of peptide-based drugs. Founded in 2006, the company is headquartered in Newark, California. Protagonist Therapeutics Inc. focuses on discovering and developing novel therapeutics for the treatment of various diseases, including inflammatory bowel disease (IBD), gastrointestinal (GI) disorders, and other serious conditions. The company utilizes its proprietary peptide technology platform to design and optimize peptide drugs, aiming to provide targeted and effective treatments for patients in need. With a strong commitment to innovation and clinical research, Protagonist Therapeutics Inc. continues to strive towards advancing the field of peptide-based therapeutics for improved patient outcomes.

Who are the main competitors of Protagonist Therapeutics in the market?

The main competitors of Protagonist Therapeutics Inc in the market include companies such as Amgen Inc, Gilead Sciences Inc, Pfizer Inc, and Roche Holding AG.

In which industries is Protagonist Therapeutics primarily active?

Protagonist Therapeutics Inc is primarily active in the pharmaceutical industry.

What is the business model of Protagonist Therapeutics?

The business model of Protagonist Therapeutics Inc revolves around developing and commercializing peptide-based drugs for the treatment of gastrointestinal diseases and disorders. Protagonist Therapeutics Inc focuses on discovering and designing potential drug candidates to target certain biological pathways and address unmet medical needs. By leveraging its proprietary technology platform, the company aims to advance innovative therapies that have the potential to improve outcomes for patients suffering from various gastrointestinal conditions. With a strong focus on research and development, Protagonist Therapeutics Inc aims to bring novel treatments to market that can positively impact the lives of those affected by gastrointestinal diseases.

What is the P/E ratio of Protagonist Therapeutics 2024?

The Protagonist Therapeutics P/E ratio is 20.39.

What is the P/S ratio of Protagonist Therapeutics 2024?

The Protagonist Therapeutics P/S ratio is 8.13.

What is the Quality Investing of Protagonist Therapeutics?

The Quality Investing for Protagonist Therapeutics is 4/10.

What is the revenue of Protagonist Therapeutics 2024?

The expected Protagonist Therapeutics revenue is 298.16 M USD.

How high is the profit of Protagonist Therapeutics 2024?

The expected Protagonist Therapeutics profit is 118.85 M USD.

What is the business model of Protagonist Therapeutics

Protagonist Therapeutics Inc. is a biotechnology company specializing in the development of peptide therapeutics for the treatment of diseases. The company's business model aims to promote the research and development of peptide drugs through novel approaches such as proteolysis to achieve higher effectiveness for patients.

What is the Protagonist Therapeutics dividend?

Protagonist Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Protagonist Therapeutics pay dividends?

The dividend cannot currently be calculated for Protagonist Therapeutics or the company does not pay out a dividend.

What is the Protagonist Therapeutics ISIN?

The ISIN of Protagonist Therapeutics is US74366E1029.

What is the Protagonist Therapeutics WKN?

The WKN of Protagonist Therapeutics is A2AP32.

What is the Protagonist Therapeutics ticker?

The ticker of Protagonist Therapeutics is PTGX.

How much dividend does Protagonist Therapeutics pay?

Over the past 12 months, Protagonist Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Protagonist Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Protagonist Therapeutics?

The current dividend yield of Protagonist Therapeutics is .

When does Protagonist Therapeutics pay dividends?

Protagonist Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Protagonist Therapeutics?

Protagonist Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Protagonist Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Protagonist Therapeutics located?

Protagonist Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Protagonist Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Protagonist Therapeutics from 11/14/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/14/2024.

When did Protagonist Therapeutics pay the last dividend?

The last dividend was paid out on 11/14/2024.

What was the dividend of Protagonist Therapeutics in the year 2023?

In the year 2023, Protagonist Therapeutics distributed 0 USD as dividends.

In which currency does Protagonist Therapeutics pay out the dividend?

The dividends of Protagonist Therapeutics are distributed in USD.

All fundamentals about Protagonist Therapeutics

Our stock analysis for Protagonist Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Protagonist Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.